title: Abciximab in rescue coronary angioplasty after full-dose tissue-type plasminogen activator.
abstract: BACKGROUND
  Rescue angioplasty is a complex procedure because of frequent reocclusions secondary to a paradoxical pro-thrombotic effect brought about by thrombolytic therapy. Administration of abciximab may improve procedural results but its utilization in this setting is limited by the potential hemorrhagic risk. Very few data on this approach are currently available in the medical literature.
  
  
  METHODS
  After failed full-dose tissue-type plasminogen activator (tPA), 30 patients (23 males, 7 females, mean age 64 +/- 13 years) referred for rescue angioplasty received abciximab (0.25 mg/kg bolus + 0.125 mcg/kg/min x 12 hour infusion) (Abc+ group). The procedural results, hemorrhagic complications and in-hospital outcome observed in these patients were compared to those of 35 patients submitted to rescue angioplasty in the same time period (1997-1999) who did not receive abciximab (Abc- group).
  
  
  RESULTS
  In the Abc+ group, 11 patients (37%) were in Killip class 3-4, 14 (47%) had multivessel disease, and 4 (13%) had previous bypass surgery. In all Abc+ patients, factors suggestive of procedural failure were present (i.e. saphenous vein graft occlusion, intraluminal thrombus, dissection, reocclusion, slow flow). The periprocedural heparin dose was 5,000 IU in Abc+ and 100 IU/kg in Abc-patients (range 5,000-10,000 IU). The procedure was successful in 29 Abc+ (97%) and in 34 Abc- patients (97%). A hemoglobin drop > 5 g occurred in 3 Abc+ (10%) and in 4 Abc- patients (11%) with a similar incidence of blood transfusion in the two groups. In all these cases, significant bleeding occurred at the vascular access site. There were 2 in-hospital deaths in Abc+ and 1 in Abc- patients. CONCLUSIONS. Selected patients undergoing rescue angioplasty may be treated with abciximab without an undue increase in hemorrhagic complications. Larger studies are needed to confirm the feasibility of this approach and to assess its potential benefits.
authors.affiliation: Department of Cardiology, S. Bortolo Hospital, Vicenza, Italy. luigilavecchia@katamail.com
authors.forename: L
authors.initials: L
authors.lastname: La Vecchia
authors.forename: M
authors.initials: M
authors.lastname: Martini
authors.forename: M
authors.initials: M
authors.lastname: Bottero
authors.forename: G L
authors.initials: GL
authors.lastname: Spadaro
authors.forename: M
authors.initials: M
authors.lastname: Sartori
authors.forename: P
authors.initials: P
authors.lastname: Vincenzi
authors.forename: T
authors.initials: T
authors.lastname: Righetti
authors.forename: L
authors.initials: L
authors.lastname: Cischele
authors.forename: A
authors.initials: A
authors.lastname: Fontanelli
mesh_terms: D000077284:Abciximab; D000368:Aged; D000369:Aged, 80 and over; D000800:Angioplasty, Balloon; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000628:therapy*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage*; D017211:Treatment Failure
chemical_list: D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D010959:Tissue Plasminogen Activator; D000077284:Abciximab